Sign In
Last checked at 
6 Mar 2019 13:00
6 March 2019
ConvaTec Group Plc("ConvaTec" or "the Company")Director/PDMR Shareholding
The Company announces the following change in the interests of a Director in ordinary shares of 10 pence each in the share capital of the Company ("Shares").
On 6 March 2019, Frank Schulkes, the Company's Chief Financial Officer and an Executive Director, received an additional grant of shares in accordance with the Company's remuneration policy approved by shareholders, as a result of one third of Mr Schulkes' annual bonus being paid out as deferred shares as follows, such shares to vest on the third anniversary of grant:
Frank Schulkes: 28,125
The closing share price on 5 March 2019 of £1.376 was used in determining the number of shares to be granted under the deferred bonus provisions.
No consideration was paid for the grant of this award.
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 | Details of the person discharging managerial responsibilities/person closely associated | |||
a) | Name | Frank Schulkes | ||
2 | Reason for the notification | |||
a) | Position/Status | CFO | ||
b) | Initial notification/Amendment | Initial notification | ||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||
a) | Name | ConvaTec Group Plc | ||
b) | LEI | 213800LS272L4FIDOH92 | ||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of 10p each in ConvaTec Group Plc GB00BD3VFW73 | ||
b) | Nature of the transaction | Grant of restricted share award under bonus deferral subject only to a time based vesting condition | ||
c) | Price(s) and volume(s) | Price(s) N/A
| Volume(s) 28,125
| |
d) | Aggregated information - Aggregated volume - Price |
N/A | ||
e) | Date of the transaction | 6 March 2019 | ||
f) | Place of the transaction | Outside a trading venue | ||
Enquiries
Media
Bobby Leach, VP Group Corporate Affairs, ConvaTec +44 (0)7770 842 226
Alastair Elwen, Finsbury +44 (0)207 251 3801
Analysts and Investors
John Crosse, VP Investor Relations, ConvaTec +44 (0)7500 141 435
Mark Reynolds, Director Investor Relations, ConvaTec +44 (0)7551 036 625
investorrelations@convatec.com
ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92
About ConvaTec
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.
Follow the stocks
